Repligen Corporation (NASDAQ:RGEN) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 60.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,822 shares of the biotechnology company's stock after purchasing an additional 11,193 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of Repligen worth $3,979,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of RGEN. Signaturefd LLC grew its holdings in shares of Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new stake in shares of Repligen during the fourth quarter valued at $29,000. Raiffeisen Bank International AG purchased a new stake in shares of Repligen during the fourth quarter valued at $29,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Repligen during the fourth quarter valued at $40,000. Finally, Center for Financial Planning Inc. grew its holdings in shares of Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after buying an additional 193 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of Repligen stock traded up $0.40 during trading hours on Friday, reaching $127.36. The stock had a trading volume of 208,766 shares, compared to its average volume of 729,442. The stock's 50 day moving average is $126.70 and its 200 day moving average is $139.91. The firm has a market capitalization of $7.16 billion, a PE ratio of -283.02, a PEG ratio of 3.65 and a beta of 1.11. Repligen Corporation has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same quarter in the prior year, the firm earned $0.28 EPS. The company's revenue for the quarter was up 10.4% on a year-over-year basis. Equities analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

RGEN has been the topic of a number of research analyst reports. Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Royal Bank Of Canada decreased their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and a consensus target price of $172.83.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.